| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Antiviral Advisory Committee Recommends Approval For Investigational Protease Inhibitor Reyataz (Atazanavir) PRINCETON, NJ -- May 14, 2003 -- Bristol-Myers Squibb Company (NYSE: BMY) is pleased that the U.S. Food and Drug Administration's (FDA) Antiviral Drug Advisory Committee unanimously recommended to the FDA that it approve the investigational protease inhibitor atazanavir (tradename Reyataz™) for the treatment of HIV-1 infection. While the FDA is not bound by the committee's recommendation, in most cases, the FDA will follow these recommendations. Reyataz is currently undergoing review at the FDA. Bristol-Myers Squibb will continue to enroll patients in an Early Access Program (EAP), which allows eligible patients infected with HIV to receive atazanavir prior to its approval by the FDA. Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
SOURCE: Bristol-Myers Squibb Company
|